Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research report report published on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Performance

Galmed Pharmaceuticals stock opened at $7.09 on Monday. Galmed Pharmaceuticals has a fifty-two week low of $2.73 and a fifty-two week high of $23.80. The company has a market cap of $4.54 million, a PE ratio of -2.95 and a beta of 0.67. The business’s 50-day simple moving average is $4.37 and its two-hundred day simple moving average is $4.27.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 EPS for the quarter.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.